Takeda signs a Co-Development Agreement with Molecular Templates for CD38-Targeted Engineered Toxin Bodies(ETBs) for Multiple Myeloma

 Takeda signs a Co-Development Agreement with Molecular Templates for CD38-Targeted Engineered Toxin Bodies(ETBs) for Multiple Myeloma

Takeda signs a Co-Development Agreement with Molecular Templates for CD38-Targeted Engineered Toxin Bodies(ETBs) for Multiple Myeloma

Shots:

  • Takeda will provide upfront of $30M and to pay royalties on commercialization. CD38-Targeted ETBs’ development cost will be shared equally between both the parties
  • Molecular Templates will receive development, regulatory and commercial milestone payments of up to $632.5M if company exercise its co-development option, or $337.5M if it does not exercise or opts out of its co-development option
  • In Oct 2016, Takeda and Molecular signed agreement to develop CD38-targeted ETBs for oncology drug discovery programs

Click here to read full press release/ article | Ref: Molecular Templates | Image: Hesed

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post